News Releases
Joint EFGCP & DIA: Better Medicines for Children Conference
22/04/2019The joint annual EFGCP-DIA Conference took place on the 25-26 October 2018 in Brussels. The aim: taking stock of the progress achieved in the paediatric field after 10 years of the Paediatric Regulation and to discuss what could be done to optimise access to new medicines.
PARTNER Project
22/04/2019PARTNER (ERN-PAEDCAN Partner: Paediatric Rare Tumours Network – PARTNER) is a three year 3rd Health Programme funded project running from January 2018 to December 2020. The project is a collaboration
QUARTET
22/04/2019The QUARTET (Excellence in Radiotherapy for Children and Adolescents) Group is finalising the preparations in anticipation of two trials, HR-NBL-2 (High Risk Neuroblastoma) and FaR-RMS (Rhadomyosarcoma).
SURVIVORSHIP PASSPORT
22/04/2019SIOP Europe, CCI Europe and PanCare signed a Memorandum of Understanding (MoU) with the aim of establishing a long-term sustainable strategy for future cooperation on survivorship care.
PRIMAGE Project
22/04/2019PRIMAGE is devoted to developing methods of computational analysis of medical images applied to childhood cancer.
PANCARE FOLLOWUP
22/04/2019The EU-funded project, PanCareFollowUp (pancarefollowup.eu) looks at how to best deliver long-term care to survivors of childhood and adolescent cancer in Europe.
PARTNER PROJECT
11/04/2019PARTNER Project Consortium Meeting of 30 January 2019.
Message from CCI Europe – Europe Survivors Network (CCI-ESN)
05/04/2019Nothing about us without us! The visibility of long-term follow up care as well as survivorship issues have increased continually in the field of the paediatric oncology within the last years.
Pamela Kearns’s op-ed article in The Parliament Magazine
01/04/2019Pam Kearns (SIOP Europe President) calls on returning and candidate MEPs to pledge their support to paediatric oncology and haematology and sign the SIOP Europe and CCI Europe Manifesto.
European Elections 2019 Manifesto for Childhood Cancer
06/03/2019BEATING CHILDHOOD CANCER: CURE MORE AND CURE BETTER – TOWARDS ZERO DEATHS AND ZERO LATE-EFFECTS